For research use only. Not for human or animal consumption.
What it is
Sermorelin acetate is the acetate salt of a synthetic 29-amino-acid peptide corresponding to residues 1–29 of human growth hormone-releasing hormone (GHRH 1–44). The peer-reviewed literature carries the same molecule under two other names — GHRH(1-29)-NH2 and GRF(1-29)-NH2 — and a review of the GRF scaffold states the identity plainly: synthetically produced GRF1-29, named there as sermorelin, has an amino acid composition identical to the N-terminal 29 residues of natural hypothalamic GHRH1-44. [3]
Two structural details define the molecule, and both become relevant when the paperwork is checked. The C-terminal arginine is amidated rather than left as a free acid. The sequence contains a single methionine, no non-natural residues, and no D-amino acid substitutions.
The identity a vial should match:
- Chemical name: Sermorelin acetate
- Also written as: GHRH(1-29)-NH2, GRF(1-29)-NH2
- CAS number: 86168-78-7
- Molecular formula: C149H246N44O42S
- Molecular weight: 3357.93
- Form: lyophilised powder
- Storage: −20°C, desiccated, protected from light
One caveat sits inside that block. The molecular weight almost universally published for this compound — 3357.93, against formula C149H246N44O42S — describes the free peptide, not the acetate salt named on the label. Purity is measured by HPLC main peak and identity is confirmed by mass spectrometry. Clarion’s published release specification is >99% HPLC main peak, and the certificate for any given lot is issued by the third-party laboratory named on that certificate; for the current sermorelin lot that laboratory is Freedom Diagnostics Testing.
What researchers are studying
The published record on this exact molecule is real, narrow, and old. It divides into two lanes, and neither lane is about the compound as a modern research reagent.
Lane one: peptide chemistry and structure-activity work, 1984–2003. Lance and colleagues synthesised hpGRF(1-29)-NH2 — the sermorelin sequence — along with four single-residue analogs, [D-Tyr-1], [D-Ala-2], [D-Asp-3] and [N-Ac-Tyr-1], and compared the somatotroph response each produced in rat and pig models. [1] Su and colleagues incubated GRF(1-29)-NH2 in porcine plasma at 37°C and followed it by HPLC, reporting a degradation rate of t1/2 = 13 min and identifying GRF(3-29)-NH2 as the primary degradation product; the same work compared structural variants — N-terminal modification, a D-amino acid at the penultimate position, side-chain cyclization between Asp8 and Lys12 or between Lys21 and Asp25 — on that same in vitro stability measurement. [2] A later review of PEGylated GRF conjugates attributes the scaffold’s short plasma residence mostly to renal ultrafiltration and enzymatic degradation at the N terminus, and reports that mono-PEGylated isomers carrying a PEG5000 chain at Lys12 or Lys21 showed activity in vitro similar to that of hGRF1-29. [3]
Lane two: analytical chemistry, 2021–2023. Sermorelin is a prohibited analyte in sport, so anti-doping laboratories have built methods to detect it. One group investigated the in vitro metabolism of four larger GHRH synthetic analogs, sermorelin among them, in fortified urine; nineteen major metabolites were identified, synthesised, purified and characterised in house, then used as reference materials alongside the parent peptides and the sermorelin(3-29)-NH2 metabolite for LC-MS/MS method development. [4] A second group built an antibody-free, ultrafiltration-based nanoLC-HRMS/MS assay for GHRH analogues in urine with sermorelin and its metabolite among the targets, reporting detection limits of 5–25 pg/mL. [5] A third synthesised defined sermorelin sequence fragments — (1-11), (13-20) and (22-29) — and profiled their stability against human blood, trypsin and chymotrypsin by HPLC-DAD, assessing which are suitable as internal standards. [6]
Every study above is a chemistry or analytical investigation in cell-free systems, plasma, urine or animal models. None of it describes an outcome in a person, and none of it should be read that way.
What the literature does not cover. A PubMed query for “sermorelin” returns roughly 331 records, but most are GHRH-axis papers built on entirely different synthetic constructs that surface only because they share the keyword. Contemporary preclinical mechanistic work on unmodified GHRH(1-29)-NH2 is essentially absent. Nothing in the peer-reviewed record characterises research-grade sermorelin obtained outside the pharmaceutical supply chain, so the literature offers no basis for judging any particular supplier’s material — only the certificate for a specific lot does that.
How to verify a vial of sermorelin before you pay
Three checks apply to any research peptide. A named third-party laboratory issued the report, not the seller’s own bench. The lot on the certificate matches the lot on the vial. The report prints a method and a figure — HPLC main peak, mass-spec identity confirmation — rather than the word “tested.”
Four further checks are specific to this molecule, and they are the ones qualified buyers most often miss.
- Salt-form arithmetic. Gross mass in the vial is peptide plus acetate counterions plus residual water. Net peptide content is therefore lower than the stated fill unless the certificate carries a separate peptide-content assay. HPLC main-peak purity and peptide content are different measurements, and most certificates report only the first.
- Which counterion is actually present. Sermorelin purified by reversed-phase HPLC is routinely isolated as the trifluoroacetate salt; converting it to the acetate requires a deliberate salt-exchange step. A purity chromatogram cannot show which counterion is present — that needs ion chromatography or a residual-TFA assay. A vial labelled “acetate” may not be one, and the label alone does not settle it.
- The C-terminal amide. The correct molecule ends in Arg29-NH2. The free-acid version, GRF(1-29) free acid, is a genuinely different compound roughly 1 Da heavier. That difference is invisible on an HPLC purity trace and invisible on a low-resolution mass spectrometer. Amidation is confirmable only by high-resolution MS.
- The (3-29) fragment. The best-documented degradation product of this sequence is sermorelin(3-29)-NH2, formed by loss of the N-terminal Tyr-Ala dipeptide — about 234 Da. It was characterised as the primary plasma breakdown product in porcine plasma in vitro [2] and is a distinct analytical target in current anti-doping methods. [4][5] A partly degraded lot can still present a clean-looking single main peak if the chromatography does not resolve parent from fragment, and mass spectrometry run on the main peak alone will not reveal the fragment’s share.
Sermorelin is also frequently conflated in the market with other GHRH-scaffold constructs carrying D-amino acid substitutions, which differ from it by only a small mass increment, and with the much smaller GHRP-class secretagogues, which are chemically unrelated. The reference point should be the identity and purity method described on that lot’s own certificate, not the product name.
Clarion publishes a public lot ledger where a lot number resolves to that lot’s own signed third-party certificate, linked from the sermorelin product page. The
Common questions
What is sermorelin acetate, in one line? The acetate salt of a synthetic 29-amino-acid peptide matching residues 1–29 of human GHRH (CAS 86168-78-7), supplied as a lyophilised powder for research use only.
Why do sermorelin, GHRH(1-29)-NH2 and GRF(1-29)-NH2 all appear in the literature? They are three names for the same 29-residue sequence. Searching only one name misses most of the record.
Does the published molecular weight describe what is in the vial? It describes the free peptide. The vial holds the acetate salt plus residual water, so net peptide content requires a separate peptide-content assay on the certificate.
Can an HPLC purity figure confirm the molecule is the acetate salt? No. Counterion identity is determined by ion chromatography or a residual-TFA assay, not by a purity chromatogram.
How should it be stored? At −20°C, desiccated and protected from light.
Is this a medicine? No. It is a research-use-only material, not for human or animal consumption.
References
[1] Lance VA, Murphy WA, Sueiras-Diaz J, Coy DH. Biochemical and Biophysical Research Communications. 1984;119(1):265–272. PMID: 6231028. doi:10.1016/0006-291x(84)91647-4 — synthesis and comparative characterisation of GRF(1-29)-amide and four single-residue analogs.
[2] Su CM, Jensen LR, Heimer EP, Felix AM, Pan YC, Mowles TF. In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma. Hormone and Metabolic Research. 1991;23(1):15–21. PMID: 1826667. doi:10.1055/s-2007-1003601
[3] Esposito P, Barbero L, Caccia P, Caliceti P, D’Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues. Advanced Drug Delivery Reviews. 2003;55(10):1279–1291. PMID: 14499707. doi:10.1016/s0169-409x(03)00109-1
[4] Memdouh S, Gavrilović I, Ng K, Cowan D, Abbate V. Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Testing and Analysis. 2021;13(11-12):1871–1887. PMID: 34665524. doi:10.1002/dta.3183
[5] Coppieters G, Deventer K, Polet M, Van Eenoo P, Judak P. An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS. Journal of Pharmaceutical and Biomedical Analysis. 2022;214:114726. PMID: 35298973. doi:10.1016/j.jpba.2022.114726
[6] González-López NM, et al. In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides. Biomedical Chromatography. 2023;37(12):e5741. PMID: 37688464. doi:10.1002/bmc.5741
Related: How to verify a peptide certificate of analysis.
Sermorelin acetate, CAS 86168-78-7, C149H246N44O42S, MW 3357.93 (free peptide), lyophilised powder, stored at −20°C. Purity by HPLC main peak against a published >99% release specification; identity confirmed by mass spectrometry; certificate issued by the third-party laboratory named on it — for the current lot, Freedom Diagnostics Testing. For research use only. Not for human or animal consumption. Not a drug.
